Comparison · NCT04141917-e7cc30e4
Standard Influenza Surveillance Period vs Point-of-care Molecular Testing and Treatment of Influenza Period: Feasibility of Implementation of Point-of-care Molecular Testing and Treatment of Influenza in Shelters
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Standard Influenza Surveillance Period vs Point-of-care Molecular Testing and Treatment of Influenza Period: Feasibility of Implementation of Point-of-care Molecular Testing and Treatment of Influenza in Shelters. Trial comparisons, record NCT04141917-e7cc30e4. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04141917-e7cc30e4
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.379 | 0.344 | 0.416 | wilson | |
| Risk in group 2 | 0.403 | 0.369 | 0.438 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0237 | -0.0734 | 0.0263 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.941 | 0.828 | 1.07 | log | |
| Odds ratio, group 1 over group 2 | 0.905 | 0.734 | 1.12 | log | |
| Number needed to treat, for one fewer participant with the outcome on Standard Influenza Surveillance Period than on Point-of-care Molecular Testing and Treatment of Influenza Period | 42.2 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Standard Influenza Surveillance Period | Subjects exhibiting ≥ 2 ARI symptoms or new or worsening cough in the last 7 days at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab for RT-PCR testing. | 266 | 701 | OG000 |
| Group 2 | Point-of-care Molecular Testing and Treatment of Influenza Period | Subjects exhibiting ≥ 2 ARI symptoms, or new or worsening cough, in the last 48 hrs at a participating shelter complete a survey collecting demographic and clinical data, and provide a mid-turbinate nasal swab to be tested on-site with a molecular assay (Abbott ID NOW™ Influenza A \& B (Chicago, IL)) and receive an antiviral if tested positive (XOFLUZA™ or Tamiflu®) .~Point-of-care molecular testing and treatment of influenza: Eligible individuals will be tested on site with a point-of-care molecular influenza test and, if positive, offered antiviral treatment with baloxavir for those aged ≥12 years, or oseltamivir for those aged \<12 years; pregnant; breastfeeding; liver disease; or are immunosuppressed. Follow-up nasal swabs and symptom diaries will be collected from participants 2 or 3 days after receiving the antiviral, and again 5, 6, or 7 days after receiving. | 308 | 764 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Feasibility of Implementation of Point-of-care Molecular Testing and Treatment of Influenza in Shelters
- Description
- Number of participants/participant encounters with les than 48 hours between symptom onset until diagnosis with RT-PCR.
- Time frame
- Up to 24 months
- Population
Includes all participant encounters from study Years 1 and 2. 153 participant encounters were missing this data because they were asymptomatic enrollments conducted once monthly at all shelters between 11/15/2019 and 3/31/2020.
Source ClinicalTrials.gov
Trial
- Title
- Test-and-treat for Influenza in Homeless Shelters
- NCT number
- NCT04141917
- Phases
- PHASE4
- Conditions
- Influenza, Respiratory Viral Infection
- Interventions
- Point-of-care molecular testing and treatment of influenza
- Lead sponsor
- University of Washington
- Results first posted
- 2022-06-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04141917?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04141917-e7cc30e4